Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Trial Details
- NCT ID
- NCT07617285
- Phase
- PHASE1
- Sponsor
- Peking University People's Hospital
- Status
- RECRUITING
- Cancer Type
- Acute Myeloid (AML) Leukemia
- Interventions
- CAR-T cells chimeric antigen receptor T cells
- Locations (sample)
- Beijing, China|39.9075,116.39723
Key Eligibility Criteria
- Age 18-70 years (inclusive), male or female.
- Relapsed or refractory acute myeloid leukemia (R/R AML) diagnosed according to the 2022 World Health Organization classification or ELN criteria, w…
- Bone marrow blasts ≥5% by morphology.
- Estimated life expectancy \>12 weeks.
For full eligibility, visit ClinicalTrials.gov.